Differentiation of remitting neuromyelitis optica spectrum disorders from multiple sclerosis by integrating parameters from serum proteins and lymphocyte subsets

J Neuroimmunol. 2018 May 15:318:45-52. doi: 10.1016/j.jneuroim.2018.02.002. Epub 2018 Feb 8.

Abstract

Differential diagnosis for neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS) is always doubtful. To differentiate these diseases, we studied the immune status in the blood of patients with MS (n = 45) or NMOSD (n = 23) at remission phase. Remitting NMOSD patients had increased levels of CXCL13 and memory B cells, while remitting MS patients had elevated levels of galectin-9 and Th1 cells. A diagnostic model with these four variables is built to distinguish remitting NMOSD from MS with a sensitivity of 91.30%. Our diagnostic model may help to improve the differentiation of remitting NMOSD from MS.

Keywords: CXCL10; CXCL13; Galectin-9; Multiple sclerosis; Neuromyelitis optica spectrum disorder.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Biomarkers / blood*
  • Diagnosis, Differential
  • Female
  • Humans
  • Lymphocyte Subsets / immunology
  • Male
  • Middle Aged
  • Multiple Sclerosis, Relapsing-Remitting / blood*
  • Multiple Sclerosis, Relapsing-Remitting / diagnosis*
  • Multiple Sclerosis, Relapsing-Remitting / immunology
  • Neuromyelitis Optica / blood*
  • Neuromyelitis Optica / diagnosis*
  • Neuromyelitis Optica / immunology
  • Young Adult

Substances

  • Biomarkers